Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0018681 (headache)
 56,091 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

In 30 refractory hypertensives a hydrallazine beta blocker combination was added to or substituted for previous antihypertensives. Over a mean period of 12 months a good or satisfactory blood pressure response resulted in 12 patients each, while six others had an unsatisfactory outcome. (Good = diastolic pressure (DP) less than 95 mmHg; Satisfactory = deltaDP greater than 15 mmHg or DP 95-105 mmHg; Unsatisfactory = DP greater than 105 mmHg or deltaDP less than 15mmHg.) Twelve of the patients had significant renal disease with serum creatinine greater than 2 mg/100 ml, but in these there was no evidence that renal hydrallazine retention potentiated an antihypertensive effect. Those with an unsatisfactory response were receiving slightly higher doses hydrallazine and propranol when compared with good responders. The average dose of hydrallazine was 258 mg/day and of propranolol 308 mg/day. Transient headache was not uncommon at the commencement of hydrallazine therapy. Angina and vertebro-basilar insufficiency were each aggravated in one patient, but resolved with dosage adjustment. A lupuslike rash developed in one patient, a slow acetylator on 300 mg hydrallazine/day who had received a total of 92 g over eleven months. The genetically determined acetylator phenotype was assessed in 75 subjects. A little over one third were found to be rapid acetylators. Those with slow acetylator phenotype did not show a more favourable phenotype did not show a more favourable blood-pressure response to equivalent doses of hydrallazine.
 ...
PMID:Hydrallazine and beta-blockade in refractory hypertension with characterization of acetylator phenotype. 0 24

74 patients with arterial circulatory disorders have been treated with calcitonin in low dosages (0.25-0.5 mg s.c. or i.m. twice to three times weekly). In 3 women with Raynaud phenomenon in sclerodermia, previously refractory necroses of the finger-tips were cured. One woman with Raynaud disease became symptomfree. Marked improvements in the results of ergometric tests were observed in 8 out of 22 patients with intermittent claudication of the lower extremities. In 12 out of 31 patients with refractory angina pectoris, the attacks were practically eliminated. Remission of headaches of vascular origin was obtained in 6 out of 17 cases. Attacks of migraine were terminated in the incipient stage by treatment with 0.25 mg Cibacalcin.
 ...
PMID:[Treatment possibilities of arterial circulatory disorders using calcitonin]. 33 77

In a placebo-controlled double blind study 20 patients suffering from angina pectoris were treated with Stenoptin. The patients had 5 attacks at least per week and consumed 5 chwable nitrocapsules and more. Criteria of success were consumption of chewable nitrocapsules and frequency of attacks. During a 7 day preobservation period the patients received a placebo identical with Stenoptin and 20 chewable nitrocapsules. The study lasted for 8 weeks. The dose was 1 tablet 3 times per day. The attacks of the active substance group were reduced from 11 to 2 on the average, and the nitro-consumption from 16 to 2 per week. In the placebo group frequency of attack slightly increased from 10 to 11. In the active substance group the dose could be reduced to 1 tablet twice per day. The placebo group was treated with 1 Stenoptin tablet 3 times per day for another 8 weeks. Subsequently 1 tablet twice per day sufficed. Transient, nitro-induced headache occurred only in 3 test persons. Stenoptin did not cause side effects and was very effective in serious types of angina pectoris.
 ...
PMID:[Stenoptin in angina pectoris (author's transl)]. 35 61

Hemodynamic monitoring after a single dose (10 mg) of nifedipine in 27 primary hypertensive subjects (diastolic pressure greater than 110 mm Hg) documented that this calcium antagonistic agent exerts a potent arteriolar vasodilating action, which results in prompt (-21% of control at 30 minutes) and persistent (-16% of control at 120 minutes) fall in mean arterial pressure associated with a rise in cardiac output and pulse rate. The same patients received oral treatment for 3 weeks. Hourly pressure readings showed that 1) the antihypertensive response to each dose lasts 8--12 hours; and 2) nifedipine every 6 hours significantly reduced blood pressure throughout the 24 hours, without postural hypotension. Side effect were short-lasting (headache in five patients, palpitation without arrhythmias in eight patients, burning sensation in the face and legs in five patients and sporadic extrasystoles in five patients) and tended to disappear with continued treatment. Development of drug resistance, sodium retention, plasma volume expansion, renin release or angina pectoris were not observed during the study. Although these findings seem to differentiate nifedipine from other vasodilators currently used in the treatment of hypertension, broader experience and more prolonged trials with nifedipine as an antihypertensive agent will be needed before conclusions can be drawn on these particular aspects.
 ...
PMID:Treatment of hypertension with nifedipine, a calcium antagonistic agent. 37 56

With advancing age blood pressure rises in most populations with the exception of some isolated tribes. In western countries 30 to 40% of the people above the age of 60 years have casual blood pressure levels greater than or equal to 160/95 mm Hg. Advancing age per se produces a number of physiological changes related to blood pressure, such as a decrease in cardiac output, an increase in peripheral vascular resistance and a decrease in plasma renin-angiotensin-aldosterone levels. The mechanism causing the elevation in pressure with age are unknown though increased rigidity of the great vessels contributes to the rise in systolic pressure. There is a decline in the sensitivity of the baroreceptor reflex, but the contribution of this to the elevation of pressure has not be elucidated. Elderly patients with uncomplicated essential hypertension have a low cardiac output and high peripheral vascular resistance. The rise in blood pressure is associated with an increased cardiovascular morbidity and mortality even in the elderly hypertensives. The available data on the efficacy of hypotensive treatment in the elderly is scanty. There are no data proving that hypotensive therapy prolongs life. Controlled studies on the prevention of organ damage especially cerebrovascular accidents are inconclusive, showing either a significant decrease or no effect. Isolated reports illustrate, however, that drastic blood pressure reduction can provoke serious side effects, thus decreasing the quality of life. Hypotensive treatment is indicated in elderly hypertensive patients with hypertensive retinopathy grade III or IV, congestive heart failure or cerebral haemorrhage, in elderly patients with a markedly elevated diastolic blood pressure (greater than or equal to 120 mm Hg) and a trial of hypotensive therapy should be offered in milder forms of hypertension when it is accompanied by certain specific symptoms such as angina, headache and dyspnoe. The management of elderly hypertensive patients is more difficult than in the young. General measures are often not well accepted. The dose adjustment of the hypotensive agent is more critical and volume depletion or orthostatic hypotension are more likely to occur.
 ...
PMID:Aging and the cardiovascular system. 37 49

A 1.5% nonachlazin solution containing substances which promote its absorption from the gastrointestinal tract increases coronary blood flow in cats 2--3 minutes after its administration into the stomach. After single administration this solution arrests a developing attack of angina pectoris in patients, improves the findings of spiroergometry, and in regular (3 times daily) medication prevents attacks of angina pectoris or makes them occurs less frequently in the very first 24 hours. The solution is most effective in patients with a high or moderate coronary reserve and affection of one or, in a lesser degree, of two coronary arteries. The solution does not cause a drop in arterial pressure, headache or dizziness.
 ...
PMID:[Pharmacological and clinical study of the liquid drug form of nonachlazine]. 50 62

In the last decade, world literature abounds in reports of harmful side effects which develop with the use of oral contraceptives including visual problems such as partial and total clotting in the retinal veins, infections, blood in the retina, and dilated veins signalling imminent stroke. 2 particular cases treated at the Opthalmological Clinic of the Academy of Medicine in Lodz deserve consideration. M.W., a 19 year old student who had had measles and scarlet fever in childhood, reported increasing visual problems. Due to irregular menstrual periods, she had been taking the contraceptive Angravid, consisting of 1 mg ethynodiol acetate, a synthetic progestogen and .05 mg mestranol, a synthetic estrogen. After a complete examination retrobulbar neuritis with the presence of papilloedema in the eye fundus of local origin was diagnosed. She was treated for general and local infection and for the prevention of clotting. After a month all symptoms regressed. H.U., a 30 year old stomatologist, reported to the clinic, complaining of sudden and periodic visual disturbances occurring in both eyes, accompanied by severe headache pains. In childhood she had had measles and whooping cough, later frequent bouts of flu and angina. She had given birth 3 times, each a natural delivery with healthy children. Recently she had been taking the oral contraceptive femigen, consisting of 2 mg chloromadinon acetate and .05 mg mestranol. After a complete series of skull and brain tests, papilloedema with the pseudotumor syndrome cerebri was diagnosed. Intensive treatment for edema produced visible improvement and the patient was discharged.
 ...
PMID:[Ophthalmological complications after oral contraceptives (author's transl)]. 67 30

In 15 patients with coronary heart disease and typical ST-segment depression during and/or after increasing physical effort in supine cycloergometry the normalizing effect of different dosages of Molsidomine on the electrocardiogram under effort was investigated in 74 exercise tolerance tests. Already after application of 0,5 mg Molsidomine there was observed a significant positive effect in comparison to an identical workload without drug. The normalizing effect was further increased by raising the dosage ot 1 mg or 2 mg respectively. To the administration of 3 mg only 1 out of 10 patients in the trial responded with an additional normalizing effect on the ECG since the rest of the patients showed already normal ECGs on 2 mg. This dose relationship also was observed in the pressure-rate-product. There was a dose-dependent decrease from which we can conclude a relief of the working myocardium. Under effort without drug 13 of 15 patients complained about stenocardia. Under the same effort and under Molsidomine however there were no more of these complaints. Because of these results it is recommended to use 2 mg of Molsidomine as a dosage in daily routine. It is needed 2 or 3 times dialy since in previous investigations there was shown a long-lasting effect over more than 5 hours. 3 out of 15 patients showed side effects which were only weak headache or weak congestion in the head.
 ...
PMID:[The normalizing effect of ECG in exercise tolerance tests under molsidomine in different dosages (author's transl]. 67 55

The author describes a 47-year-old patient in whom lingual hemiatrophy developed one month after angina. The development of hemiatrophy was preceded by occipital headaches and pain behind the ear on the side of hemiatrophy. In the differential diagnosis the author excluded inflammatory processes neoplasms and developmental anomalies and thinks that the cause of this short-lasting hemiatrophy might have been tonsillitis with compression of the nerve by the oedematous inflamed tissues with action of bacterial toxins on the nerve.
 ...
PMID:[Short-lived semi-atrophy of the tongue]. 71 30

Modern sleep research studies have provided the practicing physician with considerable new information concerning the basic psychophysiology of sleep, the effects of medical conditions on sleep and the role of maturational and emotional factors in producing certain sleep disorders. Medical and psychiatric disorders, sleep disorders and drug-induced sleep stage alterations are studied in the sleep laboratory using the same techniques developed to analyze sleep patterns in normal subjects. After initial sleep laboratory adaptation, a profile of the sleep characteristics of various clinical conditions is obtained. This profile can be compared to sleep profiles of normal subjects as well as to the effects on sleep of subsequent experimental or therapeutic procedures. Various studies have shown that coronary artery, duodenal ulcer and nocturnal headache patients experience angina, increased gastric acid secretion and migraine or cluster headaches, respectively during REM sleep. Adult nocturnal asthamtic episodes occur out of all sleep stages while attacks of dyspnea in asthmatic children occur in all stages except stage 4 sleep. Hypothyroid patients show decreases in stages 3 and 4 sleep, while in hyperthyroid patients the percentage of time spent in stages 3 and 4 sleep is markedly increased. Enuretic episodes occur predominantly in non-rapid eye movement (NREM) sleep. Sleepwalking and night terror episodes occur exclusively out of NREM sleep, particularly from stages 3 and 4 sleep. Most child somnambulists and children with night terrors "outgrow" this disorder, suggesting a delayed maturation of the central nervous system. Stimulant drugs are effective in the treatment of the sleep attacks of narcolepsy and in treating certain cases of hypersomnia, while imipramine is an effective treatment for the auxillary symptoms of narcolepsy. Psychological disturbances are frequent in adult somnambulism and night terrors as well as in hypersomnia and insomnia. Proper pharmacologic treatment to provide symptomatic relief for insomnia is recommended to enhance the psychotherapeutic process.
 ...
PMID:Nocturnal psychophysiological correlates of somatic conditions and sleep disorders. 77 62


1 2 3 4 5 6 7 8 9 10 Next >>